Lupin’s €190m VISUfarma Deal Helps US De-Risking, Boosts Specialty Business

 
• By Vibha Ravi
  
Acquisition deal
Lupin Adds VISUfarma To Its Specialty Drugs Business In Europe (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business